| Farage |
| H Ben-Bassat |
| Biosafety Level: | 2 [Cells contain Epstein-Barr virus （EBV） ] |
| frozen |
| Medium & Serum: | See Propagation |
| suspension |
| Homo sapiens （human） |
| lymphoblast
|
| Disease: non-Hodgkin's B cell lymphoma
Derived from metastatic site: lymph node
Cell Type: B lymphocyte; |
| In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
| |
| CD10 +/-; CD11a + （LFA-1）; CD19 +; CD20 +; CD21 +; CD22 +; CD23 +; CD29 （VLA-4） +; CD38 +; CD39 +; CD40 +; CD44 +; CD54 + （ICAM-1）; CD58 + （LFA-3）; CD23 -; HLA DR + [55508] [53289] |
| Amelogenin: X
CSF1PO: 11,12
D13S317: 11,13
D16S539: 11,12
D5S818: 12
D7S820: 12
THO1: 8,9
TPOX: 9
vWA: 14,15 |
| trisomy of chromosome 11 [53289] |
| adult |
| female |
| White |
| ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C |
| Medium Renewal: Add fresh medium every 2 to 3 days （depending on cell density）
Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension in fresh medium at 3 - 5 X 10 exp5 viable cells/ml.
Maintain cultures at cell concentrations between 3 X 10 exp5 and 3 X 10 exp6 viable cells/ml. |
| culture medium 95%; DMSO, 5% |
| 24 to 36 hrs |
| Recommended medium （without the additional supplements or serum described under ATCC Medium）:ATCC 30-2001
recommended serum:ATCC 30-2020 |
| 53288: Baruch M, et al. Molecular characterization of an unusual non-Hodgkin's B-lymphoma cell line （"Farage"） lacking the ability to produce immunoglobulin polypeptide chains. Leuk. Lymphoma 21: 485-495, 1996. PubMed: 9172815
53289: Gabay C, et al. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur. J. Immunol. 63: 180-191, 1999. PubMed: 10485273
55508: Shubinsky G, et al. The effect of IL-4 on the phenotype of a human B-cell lymphoma line （Farage） lacking immunoglobulin expression. Immunol. Lett. 36: 37-42, 1993. PubMed: 8344715
55509: Shubinsky G, et al. Pathways controlling the expression of surface CD21 （CR2） and CD23 （Fc（epsilon）IIR） proteins in human malignant B cells. Leuk. Lymphoma 25: 521-530, 1997. PubMed: 9250823
55510: Shubinsky G, Schlesinger M. Kinetics of the pleiotropic effect of interleukin 4 on the surface properties of human B-lymphoma cells. Leuk. Lymphoma 15: 333-340, 1994. PubMed: 7866283
55511: Shubinsky G. The mechanism of interleukin 4-induced down-regulation of CD38 on human B cells. Cell. Immunol. 10: 87-95, 1996. PubMed: 8871604 |
